Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis

Journal of Managed Care Pharmacy

Volumn 15, Issue 7, 2009, Pages 543-555

  Goldberg, Lawrence D ^a,c   Edwards, Natalie C ^b   Fincher, Contessa ^c   Doan, Quan V ^d   Al Sabbagh, Ahmad ^e   Meletiche, Dennis M ^f  

^a MD and Associates   (United States)

^b Health Services Consulting Corporation   (United States)

^c Regional Health Outcomes and Market Access ^*  (United States)

^d Outcomes Insights Inc   (United States)

^e Geisel School of Medicine at Dartmouth   (United States)

^f EMD SERONO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; PLACEBO;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE COURSE; HEALTH CARE; HEALTH ECONOMICS; HUMAN; MONITORING; MONTE CARLO METHOD; MULTIPLE SCLEROSIS; RECURRENCE RISK; RECURRENT DISEASE; RISK REDUCTION; SENSITIVITY ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MIDDLE AGED; MODELS, ECONOMIC; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 70349878541     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.7.543     Document Type: Article

References (50)

1. National Multiple Sclerosis Society. Just the Facts: 2007-2008. General Information. 2008. Available at: http://www.nationalmssociety.org/about- multiple-sclerosis/what-is-ms/download.aspx?id=22. Accessed August 17, 2009.
2. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61(11):1528-1532 (Pubitemid 37505574)
3. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;4(5):419-425
4. Pope GC, Urato CJ, Kulas ED, Kronick R, Gilmer T. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology. 2002;58(1):37-43. (Pubitemid 34041935)
5. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696-1702 (Pubitemid 43964625)
6. O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res. 2003;3(1):17. Available at: http://www.pubmedcentral.nih.gov/picrender.fcgi? artid=201004&blobtype=pdf. Accessed August 17, 2009. (Pubitemid 38865232)
7. Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005;11(2):232-239
8. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8(6):469-476 Available at: http://www.amcp.org/data/jmcp/Research-469-476. pdf.
9. Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson KP. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients. Adv Ther. 2008;25(7):658-673
10. Fairman KA, Curtiss FR. Rethinking the "whodunnit" approach to assessing the quality of health care research - a call to focus on the evidence in evidence-based practice. J Manag Care Pharm. 2008;14(7):661-674 Available at: http://www.amcp.org/data/jmcp/661-674-FairmanCurtiss-Final.pdf.
11. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13(3):245-261 Available at: http://www.amcp.org/data/jmcp/245-61.pdf. (Pubitemid 46730893)
12. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta 1-b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health. 2004;7(5):554-568 (Pubitemid 39390836)
13. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease-modifying drugs in multiple sclerosis. BMJ. 2003;326(7388):522.
14. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-76.
15. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-294
16. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504
17. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56:1628-1636
18. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology. 1993;43(4):655-661
19. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277-1285
20. Neumann PJ. Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. Oxford: Oxford University Press; 2005. Available at: http://books.google.com/books?id=-4N414j5NXgC&pg=PA37&lpg=PA37&dq= time+horizon+US+healthcare+payers+neumann&source=bl&ots= yXB-Rc-iY&sig=C34JkRDqpT0JxAM9Dx31fA9-7VI&hl=en&ei= Z7BgSprvAsOYlAeN4N3vCQ&sa=X&oi=book-result&ct=result&resnum=1. Accessed August 17, 2009.
21. Mitoxantrone product label. August 2008. Available at: http://www.novantrone.com/assets/pdf/novantrone-prescribing-info.pdf. Accessed August 17, 2009.
22. Natalizumab product label. October 2008. Available at: http://www.tysa-bri.com/en-US/tysb/site/pdfs/TYSABRI-pi.pdf. Accessed August 17, 2009.
23. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;71(10):766-773
24. Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2001;(4):CD002002.
25. Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev. 2004;(1):CD004678.
26. Hutchinson M. Treatment adherence: what is the best that can be achieved? Int MS J. 2005;12(3):73.
27. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mutl Scler. 2005;11(1):46-50. (Pubitemid 40259974)
28. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11(3):306-309 (Pubitemid 40775187)
29. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61(4):551-554 (Pubitemid 37025380)
30. Schumacher GA, Beebe G, Kilber RF, et al. Problems of experimental trials of therapy in MS: report of the panel on evaluation of experimental trials in MS. Ann N Y Acad Sci. 1968;122:552-568
31. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452
32. Drug Topics Red Book. 112 ed. Montvale, NJ: Thomson Healthcare; 2008.
33. Centers for Medicare and Medicaid Services. 2008 Medicare Physician Fee Schedule Database. Centers for Medicare and Medicaid Services. Available at: http://www.cms.hhs.gov/Pfslookup/ (Physician Fees) and http://www.cms.hhs.gov/ ClinicalLabFeeSched/02-clinlab.asp (Clinical Diagnostic Laboratory). Accessed August 17, 2009.
34. U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Indexes. Available at: http://www.bls.gov/cpi/home.htm. Accessed August 17, 2009.
35. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology. 2002;59(10):1496-1506 (Pubitemid 35387053)
36. Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci. 2005;239(1):67-74. (Pubitemid 41617417)
37. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2006; 113(5):283-287
38. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359(9316):1453-1460 (Pubitemid 34457761)
39. Khan OA, Tselis AC, Kamholz JA, et al. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler. 2001;7(6):349-353 (Pubitemid 33138343)
40. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: Clinical studies section of labeling for human prescription drug and biologic products - content and format. January 2006. Available at: http://www.fda.gov/RegulatoryInformation/Guidances/ ucm127509.htm. Accessed May 15, 2009.
41. Schechtman E. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat - which of these should we use? Value Health. 2002;5(5):431-436
42. Mikol DD, Barkhof F, Chang P, et al.; REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903-914
43. Wolansky LJ, Haghighi MH, Sevdalis E, et al. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial. J Neuroimaging. 2005;15(3):289-290 (Pubitemid 40863668)
44. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72(23):1976-1983
45. O'Connor P. Interferon beta-1b 500mcg, interferon beta-1b 250 mcg and glatiramer acetate: primary outcomes of the Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose study. Poster presented at: American Academy of Neurology 60th Annual Meeting; Presented April 12-19, 2008; Chicago, IL.
46. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler. 2003;9(3):311-319 (Pubitemid 36681901)
47. Guo S, Bozkaya D, Ward A, et al. Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications. Pharmacoeconomics. 2009;27(1):39-53.
48. Wolinsky JS. Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability. Neurology. 1995;45(7):1245-1247
49. Rossman HS. Neutralizing antibodies to multiple sclerosis treatments. J Manag Care Pharm. 2004;10(3 Suppl B):S12-S18. Available at: http://www.amcp.org/ data/jmcp/June04Supplement1.pdf.
50. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007;68(13):977-984 (Pubitemid 46569129)